Vir Biotechnology received FDA Fast Track status for VIR-5500, aimed at advanced prostate cancer. This supports the drug's development, but it is not approval and does not show that it works.
This is a helpful step for VIR-5500's development for advanced prostate cancer. Astellas is developing the drug with Vir, but the filing does not say it is approved or show that it works.
Follow Vir Biotechnology, Inc. (VIR) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for VIR